Document is current

Article History

Received: 1 September 2023

Accepted: 7 April 2024

First Online: 25 April 2024

Declarations

:

: All human specimens were encoded to protect patient confidentiality and processed under protocols approved by the regional Ethics and Investigation Committee (Comité Ético de Investigación Clínica Regional del Principado de Asturias). Women were treated according to the guidelines used in our Institution (Fundación Hospital de Jove). Written informed consent was obtained from all donors. The study adhered to National regulations and was approved by Ethical Committee of Regional Clinical Research of the Principality of Asturias (title: Evaluation of a new therapeutic strategy for triple negative breast cancer and ovary epithelial cancer based on the secretome of mesenchymal stem cells from the uterine cervix; ref.: 99/18, 21 March 2018).

: The animal studies were conducted according to the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) and approved by the Universidad de Santiago de Compostela Ethics Committee for Animal Experiments (Project title: Breast cancer: tumor cell and stroma as therapeutic targets of stem cells and vitamin D analogues. Approval no: 15010/16/001, March 2, 2016).

: The authors declare no conflict of interest. N.E. and F.J.V are co-inventors of a patent (“Human uterine cervical stem cell population and uses thereof”) owned by GiStem Research, of which some authors are shareholders (N.E., J.S-L, L.O.G, M.L.F-S. and F.J.V). The founding sponsors had no role in the design of this manuscript, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.